What is Evoke Pharma?
Evoke Pharma operates as a specialty pharmaceutical entity dedicated to the research, development, and commercialization of therapeutic solutions for gastrointestinal disorders. The company's flagship asset, GIMOTI, represents a significant advancement in medical technology as a nasal spray formulation of metoclopramide. By targeting the symptoms of acute and recurrent diabetic gastroparesis in adults, Evoke Pharma addresses a critical unmet need in the healthcare sector. Its focus on non-oral delivery systems provides a distinct competitive advantage, allowing for improved patient compliance and more predictable pharmacokinetic profiles compared to traditional oral medications.
How much funding has Evoke Pharma raised?
Evoke Pharma has raised a total of $28.7M across 2 funding rounds:
Stock Offering
$25.2M
Stock Offering
$3.5M
Stock Issuance/Offering (2013): $25.2M, investors not publicly disclosed
Stock Issuance/Offering (2024): $3.5M, investors not publicly disclosed
Key Investors in Evoke Pharma
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Evoke Pharma?
With the recent capital deployment, Evoke Pharma is positioned to accelerate its commercialization efforts and expand the market reach of its core therapeutic portfolio. The company is expected to leverage this financing to bolster its operational infrastructure and potentially explore further clinical applications for its proprietary nasal delivery platform. As the firm transitions into a more mature phase of enterprise-level growth, the focus will likely shift toward scaling distribution channels and optimizing supply chain efficiencies to meet the rising demand for specialized GI treatments. Sustained investment in research and development will remain a cornerstone of its strategy to maintain a robust pipeline and defend its intellectual property in the competitive pharmaceutical landscape.
See full Evoke Pharma company page
